Clinical Trials Logo
  1. Home
  2. Cancer Pain
  3. NCT04243954

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Cancer Pain Clinical Trial

Official title:
Hydromorphone PCA Intravenously vs Sustained-Release Morphine Orally in Cancer Patients With Severe Pain After Successful Titration: A Multicenter, Randomized, Controlled, Phase II Trial

Clinical Trial Summary

Pain is one of the most common and fear symptoms for cancer patients, which seriously affects the quality of life in cancer patients. At present, oral opioid is the most common route to administrate cancer pain. However, the patients do not satisfy the pain administration with oral opioid after successful titration in many cases, especially the cases with severe cancer pain. Patient controlled analgesia (PCA) with hydromorphone can take analgesic effect rapidly. The aim of this trial is to compare the maintenance with hydromorphone PCA intravenously or switch to Sustained-Release Morphine orally after successful titraton with hydromorphone PCA intravenously in severe cancer pain.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04243954
Study type Interventional
Source Fujian Cancer Hospital
Contact
Status Completed
Phase Phase 2
Start date April 10, 2020
Completion date November 21, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03375515 - PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain Phase 3
Recruiting NCT03431922 - Endovascular Denervation in Patients With Cancer Pain N/A
Not yet recruiting NCT05265052 - 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain Phase 2
Withdrawn NCT05325164 - Methadone for 'Adenocarcinopathic' Pain Treatment Phase 3
Completed NCT02664987 - Analgesic Treatment for Cancer Pain in South East Asia N/A
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Active, not recruiting NCT04095234 - Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT) Phase 2
Recruiting NCT05800834 - Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT02609828 - Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy Phase 3
Completed NCT03331055 - PENS or TENS for Pain in Pancreatic Cancer N/A
Recruiting NCT05506878 - Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement N/A
Completed NCT00766831 - An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Phase 4
Recruiting NCT05051735 - PARASTOP - Paracetamol With Strong Opioids Phase 3
Not yet recruiting NCT05348174 - Randomized Controlled Trial of Virtual Reality Assisted Guided Imagery (VRAGI) for Pain in Advanced Cancer Patients. N/A
Completed NCT05209906 - An Observation Study to Assess the Efficacy and Safety of Proportional Doses of Painkyl® in Patients With Breakthrough Cancer Pain
Completed NCT03031938 - Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies Phase 3
Not yet recruiting NCT05594459 - Early Treatment With Invasive Technique in Cancer Pain Management N/A
Withdrawn NCT04666623 - Compare the Efficacy and Safety of Intranasal Esketamine in Chronic Opioid Refractory Pain Phase 2
Not yet recruiting NCT05049811 - Effects of Mobile Medicine on Cancer Patients N/A